This trial is testing a new cancer therapy that involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. The therapy is called gene transfer using anti-KRAS G12V mTCR cells.
2 Primary · 0 Secondary · Reporting Duration: 6 weeks and 12 weeks following administration of the cell product, then every 3 months x3, then every 6 months x 2 years, then per PI discretion
110 Total Participants · 2 Treatment Groups
Primary Treatment: Anti-KRAS G12V mTCR PBL · No Placebo Group · Phase 1 & 2
Age 18 - 70 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: